Compare Eli Lilly And Co (LLY) vs Motorola Solutions Inc (MSI) Price & Performance

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Motorola Solutions (MSI) trades at $443.80, down 1.04% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and net income of $2.15B, supported by a record $15.6B backlog as of Q2 2026 (Zacks Investment Research, 2026-09-28). Recent acquisitions like D-Fend Solutions for $1.5B expand its security portfolio, while a new $2B share repurchase authorization signals confidence (Business Wire, 2026-09-09).

The outlook is positive with a consensus price target of $525.86, implying 18.5% upside, and 71% of analysts rate it a Buy. Risks include elevated debt levels with a debt-to-asset ratio of 47.29% in 2025 and negative net cash flow trends, but strong public safety contract wins and AI integration in video analytics provide growth catalysts.